DG1597Z
Brachytherapy Thyroid to None with Cesium 137 (Cs-137), High Dose Rate (HDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | G Endocrine System |
| Operation | 1 Brachytherapy |
| Body Part | 5 Thyroid |
| Approach | 9 High Dose Rate (HDR) |
| Device | 7 Cesium 137 (Cs-137) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy for the endocrine system involves placing a radioactive source directly into or immediately next to a gland, such as the thyroid or an adrenal gland, rather than aiming radiation at it from outside the body. Because the source sits so close to the target tissue, it can deliver a concentrated dose to the tumor while limiting exposure to surrounding structures.
This approach is used less often for endocrine tumors than external beam therapy, but it may be chosen when a tumor is well localized and accessible, or when a patient has already received prior external radiation and cannot tolerate additional beam exposure to the area. The radioactive material can be left in place temporarily or permanently, depending on the type of source and the treatment plan developed by the radiation oncology team.
Patients typically undergo a minor procedure to place the source, followed by a defined period during which the radiation is active, after which temporary sources are removed.
Anatomy & Axis Detail
Thyroid
The thyroid gland's central neck location and radiosensitivity make it a distinctive site for brachytherapy, in which a sealed radioactive source is placed directly into or adjacent to thyroid tissue rather than delivered from an external beam. This localized approach may be used for recurrent thyroid malignancy or when prior external radiation limits further dose to surrounding tissue, allowing a concentrated dose to residual tumor while sparing the trachea, esophagus, and parathyroid glands embedded nearby. It is distinct from radioactive iodine therapy, which works through selective uptake by thyroid tissue rather than physical source placement. Because the gland is superficial and accessible, image-guided or intraoperative placement is feasible, and documentation should distinguish this technique from both iodine ablation and external beam approaches to the same organ.
Modality Qualifier: High Dose Rate (HDR)
High Dose Rate (HDR) identifies brachytherapy delivered with a radioactive source of high activity, allowing treatment to be completed in minutes per fraction, often on an outpatient basis with afterloading applicators. It contrasts with Low Dose Rate (LDR), which uses a weaker source left in place for hours to days, trading a longer treatment time for a different radiobiological effect and staffing exposure profile.
Isotope: Cesium 137 (Cs-137)
Cesium 137 (Cs-137) identifies the specific radioactive isotope used as the source in a radiation therapy procedure, most often in brachytherapy applications. Naming the isotope distinguishes the treatment's radiation source from other isotopes or from external beam techniques that carry a None qualifier. It matters clinically because different isotopes have distinct energy profiles and dosing implications.
Coding & Documentation
The operative note must document direct placement of a radioactive source in or adjacent to the endocrine gland, along with the specific gland treated, to support a code from this family. Coders should confirm whether the source was temporary or permanent, since this can affect qualifier selection and whether a separate removal procedure needs to be captured later. A common mistake is confusing brachytherapy with radioactive iodine ablation for thyroid disease, which is often administered orally or systemically rather than through direct implantation and may not be coded as a procedure in this section at all. Another pitfall is failing to code the placement device or applicator separately when the documentation calls for it under coding guidelines.